10935 results for 'IL-28A/B (IFN-lambda 2/3)'

Two drugs aimed at the same axis can give opposite results in the same disease. Blocking IL-23p19 is highly effective in psoriasis and works in Crohn’s disease. Blocking IL-17A directly is highly eff

By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr

As atherosclerosis is a complex inflammatory disease, there are many influential biomarkers that contribute to the disease’s progression as well as biomarkers from atherosclerosis related di

Understanding the Bcl-2 Pathway: Implications for Cancer Therapy The Bcl-2 family of proteins plays a pivotal role in regulating apoptosis, a crucial process for maintaining cellular

Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor

High Sensitivity Cytokine ELISA Kits & Multiplex Panels | Assay Genie

Almost any inflammatory phenotype in a mouse can be assigned to a cytokine by taking that cytokine away. Neutralisation is the most direct causal test immunology has: inject a functional-grade antibo

Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m

Complete T Helper Cell Guide: Th1, Th2, Th17 & Functions - Your Ultimate Resource from Assay GenieIn this guide, we will explore the differences between TH1 and TH2 cells, their crucial r

Double-stranded DNA in the cytosol is always a mistake. A virus has uncoated, a mitochondrion has ruptured, a micronucleus has burst, or a chromosome has been broken and left unrepaired. cGAS treats

The Th1 Pathway In this guide, we will explore the differences between TH1 and TH2 cells, their crucial roles in the immune system, and the contributions of cytokines and transcription f

Non-Human Primate (NHP) Multiplex ELISA & Cytokine Panels | Assay Genie

The fight against B cell cancers, a challenging spectrum of hematologic malignancies, has entered a new era with the introduction of rituximab biosimilars. These biosimilars promise to extend the

Dozens of cytokines converge on four kinases and seven transcription factors. That compression is the problem JAK–STAT has to solve, and it is why this map is drawn as receptor, kinase and STAT colum